159 related articles for article (PubMed ID: 20615140)
1. Effects of silencing RET/PTC1 junction oncogene in human papillary thyroid carcinoma cells.
Gilbert-Sirieix M; Ripoche H; Malvy C; Massaad-Massade L
Thyroid; 2010 Oct; 20(10):1053-65. PubMed ID: 20615140
[TBL] [Abstract][Full Text] [Related]
2. Effects of silencing the RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-cholesterol.
Ali HM; Maksimenko A; Urbinati G; Chapuis H; Raouane M; Desmaële D; Yasuhiro H; Harashima H; Couvreur P; Massaad-Massade L
Thyroid; 2014 Feb; 24(2):327-38. PubMed ID: 23885719
[TBL] [Abstract][Full Text] [Related]
3. Effects of siRNA on RET/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations.
Ali HM; Urbinati G; Chapuis H; Desmaele D; Bertrand JR; Couvreur P; Massaad-Massade L
PLoS One; 2014; 9(4):e95964. PubMed ID: 24759995
[TBL] [Abstract][Full Text] [Related]
4. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
Henderson YC; Fredrick MJ; Clayman GL
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
[TBL] [Abstract][Full Text] [Related]
5. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
Liu RT; Chou FF; Wang CH; Lin CL; Chao FP; Chung JC; Huang CC; Wang PW; Cheng JT
Thyroid; 2005 Apr; 15(4):326-35. PubMed ID: 15876154
[TBL] [Abstract][Full Text] [Related]
6. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.
Rhoden KJ; Unger K; Salvatore G; Yilmaz Y; Vovk V; Chiappetta G; Qumsiyeh MB; Rothstein JL; Fusco A; Santoro M; Zitzelsberger H; Tallini G
J Clin Endocrinol Metab; 2006 Jun; 91(6):2414-23. PubMed ID: 16595592
[TBL] [Abstract][Full Text] [Related]
7. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
[TBL] [Abstract][Full Text] [Related]
8. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Ruan M; Liu M; Dong Q; Chen L
J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
[TBL] [Abstract][Full Text] [Related]
9. Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells.
Ameziane-El-Hassani R; Boufraqech M; Lagente-Chevallier O; Weyemi U; Talbot M; Métivier D; Courtin F; Bidart JM; El Mzibri M; Schlumberger M; Dupuy C
Cancer Res; 2010 May; 70(10):4123-32. PubMed ID: 20424115
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma.
Raouane M; Desmaele D; Gilbert-Sirieix M; Gueutin C; Zouhiri F; Bourgaux C; Lepeltier E; Gref R; Ben Salah R; Clayman G; Massaad-Massade L; Couvreur P
J Med Chem; 2011 Jun; 54(12):4067-76. PubMed ID: 21561161
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity.
Zhu Z; Ciampi R; Nikiforova MN; Gandhi M; Nikiforov YE
J Clin Endocrinol Metab; 2006 Sep; 91(9):3603-10. PubMed ID: 16772343
[TBL] [Abstract][Full Text] [Related]
12. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.
Mechler C; Bounacer A; Suarez H; Saint Frison M; Magois C; Aillet G; Gaulier A
Br J Cancer; 2001 Dec; 85(12):1831-7. PubMed ID: 11747322
[TBL] [Abstract][Full Text] [Related]
13. Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma.
Rhoden KJ; Johnson C; Brandao G; Howe JG; Smith BR; Tallini G
Lab Invest; 2004 Dec; 84(12):1557-70. PubMed ID: 15502856
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
Henderson YC; Ahn SH; Kang Y; Clayman GL
Clin Cancer Res; 2008 Aug; 14(15):4908-4914. PubMed ID: 18676765
[TBL] [Abstract][Full Text] [Related]
15. The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation.
Buckwalter TL; Venkateswaran A; Lavender M; La Perle KM; Cho JY; Robinson ML; Jhiang SM
Oncogene; 2002 Nov; 21(53):8166-72. PubMed ID: 12444552
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040.
Henderson YC; Ahn SH; Clayman GL
Arch Otolaryngol Head Neck Surg; 2009 Apr; 135(4):347-54. PubMed ID: 19380355
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1.
Lanzi C; Cassinelli G; Cuccuru G; Zaffaroni N; Supino R; Vignati S; Zanchi C; Yamamoto M; Zunino F
Cell Mol Life Sci; 2003 Jul; 60(7):1449-59. PubMed ID: 12943231
[TBL] [Abstract][Full Text] [Related]
18. RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.
De Falco V; Castellone MD; De Vita G; Cirafici AM; Hershman JM; Guerrero C; Fusco A; Melillo RM; Santoro M
Cancer Res; 2007 Jan; 67(1):381-90. PubMed ID: 17210721
[TBL] [Abstract][Full Text] [Related]
19. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
20. RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho.
Barone MV; Sepe L; Melillo RM; Mineo A; Santelli G; Monaco C; Castellone MD; Tramontano D; Fusco A; Santoro M
Oncogene; 2001 Oct; 20(48):6973-82. PubMed ID: 11704822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
